The assessment of nuchal translucency and serum markers for down syndrome screening with ductus venosus Doppler measurements in the first trimester

Down sendromu taramasında birinci trimester nukal kalınlık ve serum belirteçlerinin duktus venozus doppler ölçümü ile değerlendirilmesi

Özlem Özer, Cenck N. Sayın, Füsun G. Varol

Department of Obstetrics and Gynecology, Faculty of Medicine, Trakya University, Edirne, Turkey

Abstract

Objective: The aim of the study was to improve nuchal translucency (NT) and serum marker Down syndrome (Tri21) screening methods by including fetal ductus venous (DV) Doppler measurements.

Material and Methods: A total of 213 pregnant women were screened consecutively by combining maternal age, fetal NT and maternal serum pregnancy associated plasma protein A (PAPP-A) and free β-human chorionic gonadotropin (f-β-HCG) values at 11-14 weeks of gestation. Also, a DV Doppler analysis was performed for the contribution to the screening for Tri21 and other fetal anomalies or adverse pregnancy outcomes.

Results: Twelve fetuses had DV PI measurements above the 95th percentile and two (17%) developed intrauterine growth retardation. DV PI values negatively correlated with birth weight (p=0.013, r=0.171). PAPP-A was <0.4 MoM in 23, and f-β-HCG was elevated >1.91 MoM in 49 patients. The rates of false positivity were 10% for PAPP-A and 22% for f-β-HCG. The sensitivity, specificity, positive and negative predictive values of the combined test was 100%, 95%, 20% and 100%, respectively.

Conclusion: The combined test has high sensitivity and specificity for Tri21 detection. The addition of DV Doppler ultrasound in the first trimester might have the advantage of predicting some adverse pregnancy outcomes. However, in the Turkish population, further studies with larger numbers of patients will be needed to establish the usefulness of DV for the detection of Tri21 or the prediction of some major cardiac anomalies.

Key words: Turkish population, Down syndrome, combined test, ductus venosus

Introduction

Prenatal screening for Down syndrome (Tri21) was developed by the introduction of nuchal translucency (NT) and ultrasound to the first trimester of pregnancy. In pregnancies with fetal Tri21, low maternal serum pregnancy associated plasma protein A (PAPP-A) and elevated free β-human chorionic gonadotropin (f-β-HCG) values were observed by the 1990s (1, 2). Screening for Tri21 by combining maternal age, fetal NT thickness and maternal serum f-β-HCG and PAPP-A at 11-13 weeks was associated with a detection rate of about 90% for a false-positive rate of 5% (3, 4). However, since measurements of NT varied considerably between centers and clinicians, the sensitivity can be as low as 31%, thus it could hardly be reliably incorporated into the test (5). Doppler ultrasound of the ductus venosus (DV) has also been added to expert antenatal screening programs for chromo...
somal abnormalities. An association between abnormal flow in the DV and fetal aneuploidy has been introduced. The use of DV velocimetry in combination with NT has been asserted as better than either test alone, since it increased the sensitivity in the detection of Tri21 (6-11). In fetuses with cardiac defects or fetal hypoxia some abnormal patterns of the "a" wave on DV, which represents atrial contraction, can be observed (12). Matias et al. analyzed fetuses at 10-14 weeks of gestation with increased NT and found that 57 of 63 had chromosomal defects, whereas only 13 out of 423 with normal chromosome had abnormal DV flow patterns (13). Likewise, in fetuses with Tri21, absence of flow or reverse flow of the "a" wave can be observed (14).

In this study, our aim was to improve Tri21 screening methods based on NT and serum markers by including fetal DV Doppler measurements.

Materials and Methods

The study was performed in Trakya University Faculty of Medicine, Department of Obstetrics & Gynecology, on 213 consecutive pregnant women aged between 18 and 43 years admitted for antenatal care at 11-14 weeks of gestation. Twins or higher order pregnancies, pregnancies ending in spontaneous abortion or with congenital anomalies detected at the first trimester and patients that did not deliver in our clinic or were lost during follow-up were excluded from the study. All patients were delivered in our department and the newborns were examined after birth for possible anomalies, in the Neonatology Department by a pediatrician. The study was approved by the Ethics Committee for Human research at Trakya University, Turkey, and informed consent was obtained from the patients. The study population consisted of Turkish women living in the Trakya Region of Turkey. Gestational age was based on the last menstrual period and according to a reliable menstrual history confirmed by ultrasonography.

Age, maternal smoking habit, previous fetuses with anomalies, presence of diabetes were noted, height and weight were obtained and body mass index calculated from all women. A detailed structural survey by ultrasound (Shimadzu SDU-2200, Japan) was performed on each fetus with a 3.5 MHz transabdominal transducer. Crown rump length (CRL), NT and DV flow patterns were measured by the same clinician (OV) during periods without uterine contractions and in the absence of fetal body movements. Three measurements for NT were obtained and the highest was accepted for calculation of risk for the combined test.

The pulsatility (PI) of DV was estimated from the Doppler waveforms. The mean value assessed from five consecutive waveforms was analyzed. Color Doppler imaging was used to optimize placement of the pulsed wave Doppler gate by adjusting the velocity scale to identify area and direction of maximum blood flow. The size of the sample gate was enlarged to encompass the entire vessel, and transducer position was adjusted to eliminate aliasing, in order to minimize the Doppler angle. All measurements were obtained from the sagittal plane of the fetus. DV was identified from where it appeared from the umbilical vein and all measurements were taken from the beginning of the vessel since the flow pattern changes from the beginning to the end of DV.

Blood samples were obtained from the subjects through venipuncture to perform the PAPP-A and f β-HCG assays. Samples were assayed immediately. Serum concentrations of PAPP-A and f β-HCG were all analyzed by chemiluminescent immunometric assays (Immulite 2000, Diagnostic Products Co., LA, USA), following the instructions of the manufacturers. All values were calculated by multiples of median (MoM) according to gestational age. Risk analysis for trisomies was made by the computer program PRISCA version 3.4. In this first trimester biochemical tests, values <0.4 MoM for PAPP-A, and >1.91 MoM for f β-HCG were accepted as high risk for Tri21 as suggested (15). 'Screen-positive' risk for Tri21, based on combined PAPP-A, f β-HCG and NT was accepted with a cut-off ≥ 1: 250. A second level genetic ultrasound examination was performed on all patients for anomaly screening at 18-23 weeks. Amniocentesis for chromosomal anomalies was carried out in women who had a high risk according to the first trimester screening or had anomalies in genetic ultrasound, as suggested (16, 17).

Data were stored and analyzed by SPSS program (Statistical Package for Social Science, release11.0; SPSS, Chicago, IL) for Windows. Kruskal-Wallis test was used for inter-group comparisons of normally-distributed variables. Continuous variables were analyzed with student t-test if distributional assumptions were consistent with normality. Otherwise, we performed Mann-Whitney U tests for the parameters that were not normally distributed. Spearman and Pearson correlation analysis was used for linear correlations. A P value less than 0.05 was considered statistically significant.

Results

Mean±SD age, gestational age at admittance, and gestational age at delivery were 27.8±4.9 years, 12.4±0.72 and 38.1±1.5 weeks, respectively. Only 20 (9.4%) women were older than 35 years. Twenty-four women (11%) were smokers. Mean weight at delivery was 3278±445 (min. 1090, max. 4260) gr., of which 117 (56%) were boys (3345±443 gr.) and 94 (44%) were girls (3199±435 gr.). Birth weight was significantly higher in boys (p=0.017). Ten amniocenteses were performed in women ≥ 35 years (n=20) and no Tri21 syndrome was detected.

Mean CRL, NT, DV PI values were 58.5 9.1 mm, 1.16±0.3 mm and 1.05±0.13, respectively. Fetal heart rate measurements were calculated by multiples of median (MoM) according to gestational age. Risk analysis for trisomies was made by the computer program PRISCA version 3.4. In this first trimester biochemical tests, values <0.4 MoM for PAPP-A, and >1.91 MoM for f β-HCG were accepted as high risk for Tri21 as suggested (15). 'Screen-positive' risk for Tri21, based on combined PAPP-A, f β-HCG and NT was accepted with a cut-off ≥ 1: 250. A second level genetic ultrasound examination was performed on all patients for anomaly screening at 18-23 weeks. Amniocentesis for chromosomal anomalies was carried out in women who had a high risk according to the first trimester screening or had anomalies in genetic ultrasound, as suggested (16, 17).

Data were stored and analyzed by SPSS program (Statistical Package for Social Science, release11.0; SPSS, Chicago, IL) for Windows. Kruskal-Wallis test was used for inter-group comparisons of normally-distributed variables. Continuous variables were analyzed with student t-test if distributional assumptions were consistent with normality. Otherwise, we performed Mann-Whitney U tests for the parameters that were not normally distributed. Spearman and Pearson correlation analysis was used for linear correlations. A P value less than 0.05 was considered statistically significant.
nonsignificantly with the development of pregnancy (Table 3). Ten women had PAPP-A values under the 5th percentile, whereas 9 had fβ-HCG above the 95th percentile. Smoking habits and sex did not correlate with PAPP-A and fβ-HCG values (P > 0.05). PAPP-A was <0.4 MoM in 23, and fβ-HCG was > 1.91 MoM in 49 patients. The rates of false positivity were 10% for PAPP-A and 22% for fβ-HCG. In patients who had PAPP-A <0.4 MoM, 2 had Tri21 syndrome detected by amniocentesis and were terminated, whereas 17 (74%) had uneventful pregnancy outcomes. One patient had pericentric translocation on the 9th chromosome which had no effect on phenotype, 2 had IUGR and one developed gestational hypertension. However, in another 5 patients who developed IUGR, PAPP-A values were >0.4 MoM. In patients who had fβ-HCG > 1.91 MoM, one had had Tri21 and was terminated, 37 (75%) had uneventful pregnancy outcomes.

Five (10%) had IUGR (one of which had also PAPP-A <0.4 MoM), one had coarctation of the aorta, 2 developed gestational diabetes, 1 preeclampsia, 2 threatened preterm labor.

Ten patients (4.7%) had high risk for Tri21 according to the combined test (risk ≥1/250) and 2 fetuses had Tri21 detected by amniocentesis. Two women had a high risk on combined test, but did not accept amniocentesis. However, neither had adverse pregnancy outcomes nor any fetal anomaly detected at birth. The sensitivity, specificity, positive and negative predictive values of the combined test was 100%, 95%, 20% and 100%, respectively.

Amniocentesis was performed in 21 patients (9.8%). Indications were maternal age (n=10), high risk in screening test (n=8), findings on genetic ultrasound (n=2) and history of recurrent abortion (n=1).

Two cardiac anomalies were observed in the study group. One had coarctation of the aorta and the other had secundum type atrial septal defect with duodenal atresia. Both fetuses had normal phenotype and normal NT, PAPP-A and DV PI values, whereas one had a fβ-HCG level above the 95th percentile. However, these two abnormalities could not be detected by the II level ultrasound.

### Discussion

The most sensitive method for Tri21 screening was introduced as the combination of maternal age, serum screening for PAPP-A, fβ-HCG with fetal NT with 90% detection and 5% false positive rate (18). Nearly 70% of fetuses with Tri21 are born of mothers <35 years-old (19). Similarly, our two patients with Tri21 fetuses were below age 35. Also, not only did the amniocentesis reveal no Tri21, no case was found in patients who did not accept amniocentesis in women >35 years in our study. In a study evaluating NT in a low risk population of 1473 women, only 67% of fetuses with Tri21 would have been detected with a 24% invasive testing rate, if the only screening criteria was maternal age. If NT measurement had been added to the screening policy, the sensitivity would have been 100% with a 19.1% invasive testing rate (20). In the study by Snijders et al. (3) the estimated Tri21 risk, from maternal age and fetal NT, was 1 in ≥ 300 in 7907 (8.3%) of 95476 normal pregnancies, but in 268 (82.2%) of 326 with Tri21. The number of invasive procedures performed to detect one Tri21 was calculated as 30. In line with that study, others observed that the main benefit of the addition of first trimester NT measurements to the screening protocol was a very high detection rate with a moderate false-positive rate (21). Different studies have used the combined test for the screening of chromosomal anomalies in low and high risk populations, or used pooled data with patients with Tri21 and reported a detection rate of about 80% (18, 22-24). The detection rate of Tri21 with only NT measurement was reported as 77%, with a 5% false positive rate (3). However, biochemistry tests alone, consisting of PAPP-A and fβ-HCG, detected about 60% of the cases with 5% false positive rate (5, 24). For screening purposes, a cut-off threshold value for NT of ≥3 mm gave a sensitivity ≥50%, a false positive rate <5% and a positive predictive value >1% for chromosomal anomalies (25). In our study, only one case had NT> 3 mm. If only NT was considered for screening of Tri21, the sensitivity would have been 50%, specificity 100%, positive and negative predic-

### Table 1. Percentiles for fetal nuchal translucency and for ductus venous pulsatility index

| Gestational weeks | NT | DV |
|-------------------|----|----|
|                  | 5th | 10th | 95th | 5th | 10th | 95th |
| 11-11.4           | 0.72 | 0.83 | 1.56 | 0.66 | 1.02 | 1.27 |
| 11.5-11.9         | 0.73 | 1.04 | 1.50 | 0.78 | 1.08 | 1.23 |
| 12-12.4           | 0.76 | 1.10 | 1.48 | 0.83 | 1.03 | 1.26 |
| 12.5-12.9         | 0.91 | 1.25 | 1.64 | 0.79 | 1.06 | 1.26 |
| 13-13.4           | 0.85 | 1.29 | 2.80 | 0.88 | 1.13 | 1.28 |
| 13.5-14           | 0.86 | 1.42 | 1.77 | 0.77 | 1.08 | 1.26 |

DV: Ductus venosus; NT: Nuchal translucency; p: Percentile

### Table 2. Calculated parameters in pregnancies with Down syndrome

| Case | Age (CRL) | NT (mm) | PAPP-A (MoM) | fβ-HCG (MoM) | DV PI | Combined test risk |
|------|-----------|---------|--------------|--------------|-------|-------------------|
| 1    | 27        | 66.9    | 3.6          | 0.39         | 2.31  | 0.98              | 1/50 |
| 2    | 26        | 66.7    | 1.6          | 0.2          | 1.7   | -                 | 1/114 |

CRL: Cranium rump length; DV PI: Ductus venosus pulsatility index; fβ-HCG: free β human chorioclastic gonadotropin; NT: Nuchal translucency; PAPP-A: Pregnancy associated protein A

### Table 3. Calculated multiples of median (MoM) values for pregnancy associated protein A (PAPP-A) and free β human chorioclastic gonadotropin (fβ-HCG) in the whole group

| Gestational weeks | PAPP-A | fβ-HCG |
|-------------------|--------|--------|
|                  | 5th    | 10th   | 95th   | 5th    | 10th   | 95th   |
| 11-11.4           | 0.42   | 0.87   | 2.16   | 0.26   | 1.22   | 5.04   |
| 11.5-11.9         | 0.31   | 0.88   | 1.79   | 0.41   | 1.14   | 6.88   |
| 12-12.4           | 0.34   | 0.75   | 1.55   | 0.48   | 1.33   | 3.15   |
| 12.5-12.9         | 0.22   | 0.70   | 1.91   | 0.52   | 1.35   | 5.61   |
| 13-13.4           | 0.24   | 0.66   | 1.25   | 0.55   | 1.28   | 5.09   |
| 13.5-14           | 0.29   | 0.60   | 1.33   | 0.67   | 1.22   | 2.81   |

fβ-HCG: free β human chorioclastic gonadotropin; PAPP-A: Pregnancy associated protein A; p: Percentile
tive values 100% and 99%. Likewise, according to our results, the sensitivity, specificity and positive and negative predictive values of the combined test were 100%, 95%, 20% and 100%, respectively. However, these high rates seem to result from the limited number of patients in our study.

The effect of smoking on PAPP-A and fβ-HCG values has been defined (26). We did not find any effect of smoking on biochemical markers of the combined test. Smoking reduced serum PAPP-A and fβ-HCG levels in women who smoked ≥5 cigarettes a day in a Turkish population (27). However, it was demonstrated that the effect of adjusting for smoking on the combined test is small, with an estimate of less than half percentage point increase in the detection rate (28). Smoking decreases trophoblast invasion and proliferation (29, 30). So the clinical effect on placental function may be obvious by IUGR. However, in our study smoking neither decreased PAPP-A nor had a relationship with the development of IUGR. Besides, out of 213 patients, 23 had PAPP-A<0.4 MoM; 2 had Tri21 and 2 (9.5%) developed IUGR. In the other 5 fetuses that developed IUGR, PAPP-A values were within normal limits. Thus, PAPP-A, the marker for placental function, has not been shown to predict IUGR.

The reference range for DV PI has been shown to have a biphasic pattern; with an initial non-significant increase up to a CRL of 63 mm and a fall thereafter, as in our study (31). Doppler studies of the DV have been applied as an adjunct to NT measurements. In 1998, increased DV PI values above the 95th percentile have been observed in 73% of the fetuses with Tri21 between the 10th and 18th weeks (14). In a further study, the same investigators found that the median DV PI in Tri21 was 1.70 times higher than in unaffected pregnancies in women between 10 and 14 weeks. Also, the addition of PI to NT alone will increase the detection rate from 76 to 85%, and, combined with serum markers, from 88 to 92% (8). Murta et al. analyzed absent or reversed flow during atrial contraction in 93.1% of chromosomally abnormal fetuses (32). However, abnormal ductal blood flow was observed in 5.2% of euploid fetuses and 70.8% of fetuses with Tri21 (6). Inclusion of DV flow in first-trimester screening by maternal age, fetal NT and maternal serum free β-HCG and PAPP-A would detect about 96% of trisomy 21 fetuses at a false-positive rate of about 2.5% (6). Assessment of DV flow is time consuming and requires appropriately trained sonographers, and sonographers with extensive experience in the first trimester scan require an average of 80 examinations to achieve this level of competence (33). The alternative strategy is to reserve this examination for the subgroup of pregnancies with an intermediate risk (between one in 51 and one in 1000) after combined fetal NT, FHR, free β-HCG and PAPP-A screening. Even when NT is normal, reverse flow during atrial contraction in DV has a strong association which predicts adverse outcome such as IUGR, cardiovascular abnormalities and renal abnormalities (34). Although we could not measure the flow pattern in a case with Tri21 in our study, the addition of DV Doppler to the combined test did not improve the detection of Tri21 or the development of IUGR and cardiovascular abnormalities. In line with our results, some authors observed a lack of correlation of DV PI values with NT or with serum markers (8, 10), but the association between reversed a-wave on DV and increased NT may be explained by the coincidence of cardiac defects or transient cardiac dysfunction (6). Abnormal DV flow may result from abnormal cardiac preload, cardiac compliance or afterload. When there is an overlap in the pathophysiology leading to an increased NT and abnormal DV blood flow, their combination improved the sensitivity and specificity of aneuploidy prediction (13).

Matas et al. (13) observed significantly higher DV PI values in Tri21,18,13,Turner syndrome and triploidy, but multivariate regression analysis demonstrated that only the height of the a wave provided a significant independent contribution in distinguishing between the chromosomally normal and abnormal groups. We did not find any absent or reverse flow during atrial contraction on DV Doppler, but 12 fetuses had DV PI >95th percentile and 2 (17%) developed IUGR in the third trimester, while DV PI negatively correlated with birth weight in our study. The first case with Tri21 and the other two cases with cardiac defects without chromosomal anomaly also revealed normal flow patterns. Favre et al. (35) observed abnormal flow and increased NT in 36% of fetuses with a normal chromosome but a major cardiac defect, and the authors have concluded that in chromosomally normal fetuses with increased NT, assessment of DV blood flow velocimetry could improve the predictive capacity for an underlying major cardiac defect. However, we could not find any pathologic pattern of flow in DV in our two cases.

In conclusion, the combined test has a distinctive effect on Down syndrome detection with high sensitivity and specificity. The addition, DV Doppler ultrasound might have the advantage of predicting some adverse pregnancy outcomes. However, further studies in the Turkish population will be needed to rectify these screening tests; in the current study we could not establish the usefulness of DV Doppler analysis for the detection of Tri21 or the prediction of some major cardiac anomalies.

Conflict of interest
None declared.

References
1. Brambati B, Macintosh MC, Teisner B, Maguinnes S, Shirmanker K, Lanzani A, et al. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993; 100: 324-6.
2. Spencer K, Macri JN, Atiken DA, Connor JM. Free beta-hCG as first-trimester marker for fetal trisomy. . Lancet 1992; 339: 1480.
3. Snijders RJ, Noble P, Sehäre N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-6.
4. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multi-center study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-6.
5. Haddow JE, Palomaki GE, Knight GI, Williams J, Miller VA, Johnson A. Screening of maternal serum for fetal Down’s syndrome in the first trimester. N Engl J Med 1998; 338: 955-61.
6. Maiz N, Valencía C, Kagan KO, Wright D, Nicolaides KH. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 512-7.
7. Matias A, Montenegro N. Ductus venosus blood flow in chromosomally abnormal fetuses at 11 to 14 weeks of gestation. Semin Perinatal 2001; 25: 22-7.
8. Borrell A, Gonce A, Martinez JM, Borobio V, Fortuny A, Coll O, Cucke H. First-trimester screening for Down syndrome with duc-
tus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn 2005; 25: 95-10.
9. Mavridis E, Sairam S, Hollis B, Thilaganathan B. Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus. BJOG 2002; 109: 1015-9.
10. Antolín E, Comas C, Torrents M, Muñoz A, Figueras F, Echevarría M, et al. The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10-16 weeks of gestation. Ultrasound Obstet Gynecol 2001; 17: 295-300.
11. Canda MT, Demir N. Contemporary screening in pregnancy. J Turkish-German Gynecol Assoc 2007; 8: 331-8.
12. Montenegro N, Matias A, Areias JC, Castedo S, Barros H. Increased fetal nuchal translucency: possible involvement of early cardiac failure. Ultrasound Obstet Gynecol 1997; 10: 265-8.
13. Matias A, Gomes C, Flack N, Montenegro N, Nicolaides KH. Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol 1998; 12: 380-4.
14. Borrell A, Antolín E, Costa D, Farre MT, Martínez JM, Fortuny A. Abnormal ductus venosus blood flow in trisomy 21 fetuses during early pregnancy. Am J Obstet Gynecol 1998; 179: 1621-7.
15. Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999; 23: 359-68.
16. Breathnach FM, Fleming A, Malone FD. The second trimester genetic sonogram. Am J Med Genet C Semin Med Genet 2007; 145C: 62-72.
17. Yigler AB, Kavak ZN, Baki čı N, Gokaslan H. Effect of smoking on pregnancy-associated plasma protein A, free human chorionic gonadotropin and nuchal translucency. BJOG 2003; 110: 664-7.
18. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7.
19. Chew S, Anandakumar C, Ratnam SS. Maternal serum markers for Down’s syndrome pregnancies. Singapore Med J 1995; 36: 417-23.
20. Pajkrt E, Mol BW, van Lith JM, Bleker OP, Bilardo CM. Screening for Down’s syndrome by fetal nuchal translucency measurement in a high-risk population. Ultrasound Obstet Gynecol 1998; 12: 156-62.
21. Tercanli S, Holzgreve W, Batukan C, Gerber A, Ermis H, Miny P. Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland. Ultraschall Med 2002; 23: 22-6.
22. Wald NJ, Hackshaw AK. Combining ultrasound and biochemical screening in first-trimester screening for Down’s syndrome. Prenat Diagn 1997; 17: 821-9.
23. De Biasio P, Siccardi M, Volpe G, Fumaluro L, Santì F, Canini S. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy—the combined test. Prenat Diagn 1999; 19: 360-3.
24. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down’s syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109: 667-76.
25. Charasson T, Ko-Kivok-Yun P, Martin F, Sarramon MF. Screening for trisomy 21 by measuring nuchal translucency during the first trimester of pregnancy. J Gynecol Obstet Biol Reprod 1997; 26: 671-8.
26. Niemimaa M, Heinonen S, Seppala M, Rynnamen M. The influence of smoking on the pregnancy-associated plasma protein A, free human chorionic gonadotropin and nuchal translucency. BJOG 2003; 110: 664-7.
27. Bestwick JP, Huttly WJ, Wald NJ. First trimester Down’s syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotrophin, pregnancy-associated plasma protein-A and nuchal translucency. J Med Screen 2008; 15: 204-6.
28. Demir R, Demir Ay, Yinanc M. Structural changes in placental barrier of smoking mother. A quantitative and ultrastructural study. Pathol Res Pract 1994; 190: 665-67.
29. Genbacev O, Bass KE, Joslin RJ, Fisher SJ. Maternal smoking inhibits early human cytotrophoblast differentiation. Reprod Toxicol 1995; 9: 245-55.
30. Teixeira LS, Leite J, Viegas MJ, Faria MM, Chaves AS, Teixeira RC et al. Ductus venosus Doppler velocimetry in the first trimester: a new finding. Ultrasound Obstet Gynecol 2008; 31: 261-5.
31. Murta CG, Moron AF, Avila MA, Weiner CP. Application of ductus venosus Doppler velocimetry for the detection of fetal aneuploidy in the first trimester of pregnancy. Fetal Diagn Ther 2002; 17: 308-14.
32. Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH. Learning curve for Doppler assessment of ductus venosus flow at 11-13 + 6 weeks. Ultrasound Obstet Gynecol 2008; 31: 503-6.
33. Oh C, Harman C, Baschat AA. Abnormal first-trimester ductus venosus blood flow: a risk factor for adverse outcome in fetuses with normal nuchal translucency. Ultrasound Obstet Gynecol 2007; 30: 192-6.
34. Favre R, Cherif Y, Kohler M, Kohler A, Hunsinger MC, Bouffet N, et al. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Ultrasound Obstet Gynecol 2003; 21: 239-43.